Social media

Open claims datasets are a goldmine for life sciences—but they come with inevitable disruptions. Whether it’s new data sources or supplier exits, knowing how to manage change is key to maintaining strategic advantage. J...

In today’s data-rich healthcare landscape, open claims datasets offer unmatched breadth and timeliness. But disruptions—whether from new sources or supplier exits—are inevitable. Join Symphony Health, an ICON plc compan...

The biotech landscape is evolving fast. ICON Biotech’s latest sector surveys reveal what’s changed since 2023, which therapeutic areas are slowing down, and which modalities are gaining momentum. Discover how global geo...

The biotech landscape is evolving fast. ICON Biotech’s latest sector surveys reveal what’s changed since 2023, which therapeutic areas are slowing down, and which modalities are gaining momentum. Discover how global geo...

From prescriptions to patient demographics, Metys®, from Symphony Health, an ICON plc company, sees it all. With over 150+ metrics – from diagnosis subgroups to payer mis – you get the full picture, not just a snapshot....

From prescriptions to patient demographics, Metys®, from Symphony Health, an ICON plc company, sees it all. With over 150+ metrics – from diagnosis subgroups to payer mis – you get the full picture, not just a snapshot....

Long-term follow-up for vaccines may seem to be a distant concern when clinical trials are just beginning, but it can be critical to have a plan for follow-up at the outset. Learn considerations for follow-up design, s...

Long-term follow-up for vaccines may seem to be a distant concern when clinical trials are just beginning, but it can be critical to have a plan for follow-up at the outset. Learn considerations for follow-up design, suc...

2025 has seen both the EMA and the FDA publish new position papers and opinions on streamlining the trial process for biosimilars. On the surface, reducing reliance on comparative efficacy trials has the potential to sav...

There is great excitement following the announcements by the FDA and EMA around streamlining the biosimilar trial process. They promise to reduce the burden on developers and therefore increase the number of more afford...

USP compounding may be fast — but is it costing you quality, compliance, and insight? In this insightful session, our experts discussed: - Why GMP manufacturing offers a strategic edge in early phase trials - Real-worl...

USP compounding may be fast — but is it costing you quality, compliance, and insight? In this insightful session, our experts discussed: - Why GMP manufacturing offers a strategic edge in early phase trials - Real-worl...